Hot Performing Stocks To Own For 2014

SAN FRANCISCO (MarketWatch) ��Energy stocks fell Friday, with Chevron Corp. the worst hit after it reported disappointing third-quarter earnings.

Chevron (CVX) �shares ended 1.6% lower, the worst-performing stock on the Dow Jones Industrial Average.

Chevron early Friday reported earnings of $2.57 a share, from $2.69 a share a year earlier. Analysts had expected earnings around $2.71 a share. The earnings miss was mostly due to weak refining margins. Chevron last month warned of significantly lower earnings for its refining, marketing, and chemicals operations.

Top 5 Communications Equipment Companies To Own In Right Now: CEPHEID(CPHD)

Cepheid, a molecular diagnostics company, engages in developing, manufacturing, and marketing integrated systems for testing in the clinical market, as well as for application in legacy biothreat, industrial, and partner markets. Its systems enable molecular testing for organisms and genetic-based diseases by automation. The company offers GeneXpert system that integrates sample preparation in addition to DNA amplification and detection; and SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample. The GeneXpert system is designed for reference laboratories, hospital central laboratories, and satellite testing locations, such as emergency departments and intensive care units within hospitals and doctors? offices. Cepheid also provides GeneXpert Infinity System for high volume testing. The company offers tests for the GeneXpert and the SmartCycler systems in the areas of healthcare associated infections, critical infectious d isease, genetics, women?s health, and oncology. These tests include U.S. Food and Drug Administration (FDA) cleared products, CE marked products, analyte specific reagents, and research use only tests in the clinical market. In the industrial market, it sells its SmartCycler system along with general use polymerase chain reaction reagents and reaction tubes. Cepheid sells its products its direct sales force and through third-party distributors worldwide. It has collaboration agreements with Novartis, Foundation for Innovative New Diagnostics, Life Technologies Corporation, and Northrop Grumman Corporation. The company was founded in 1996 and is headquartered in Sunnyvale, California.

Advisors' Opinion:

• [By Jon C. Ogg]

  Cepheid (NASDAQ: CPHD) was downgraded to Neutral from Buy at Bank of America Merrill Lynch, but the firm actually raised its price target to $41 (versus a $39.04 close).

• [By Sean Williams]

  What: Shares of Cepheid (NASDAQ: CPHD  ) , a developer of molecular diagnostic tests for both clinical and non-clinical markets, plunged as much as 11% after the company reported its second-quarter earnings results following the closing bell last night.

Hot Performing Stocks To Own For 2014: Emergent Biosolutions Inc. (EBS)

Emergent BioSolutions, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and commercialization of specialized products for use in defense and commercial markets in the United States and internationally. The company operates in two segments, Biodefense and Biosciences. It markets BioThrax, an FDA licensed vaccine for the prevention of anthrax disease; and RSDL (decontamination lotion) product for removal or neutralization of chemical warfare agents from the skin. The company�s development pipeline includes Anthrivig (Human Anthrax Immunoglobulin), a polyclonal anthrax therapeutic candidate; PreviThrax, a recombinant anthrax vaccine candidate, NuThrax (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant); BioThrax with a novel adjuvant; and Thravixa (Fully Human Anthrax Monoclonal Antibody), a therapeutic being studied for use against symptomatic anthrax infection. In addition, it develops TRU-016, a humanized anti-CD37 therapeutic candidate, ba sed on its ADAPTIR (Modular Protein Technology) platform that is in Phase I/II clinical trials to treat chronic lymphocytic leukemia. Further, the company develops preclinical product candidates targeted for solid tumors, inflammatory bowel disease, graft versus host disease, rheumatoid arthritis, and a human vaccine to protect against influenza caused by a range of circulating H5 influenza strains. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Rockville, Maryland.

Advisors' Opinion:

• [By Stephen Quickel]

  Emergent BioSolutions (EBS) is a far smaller specialist in bio-medical products for the military and commercial markets, including anthrax vaccine and decontamination agents. With revenues nearing $400 million, EBS is acquiring Canada's Cangene Corp. to expand its product line.

Hot Performing Stocks To Own For 2014: Cleco Corporation (CNL)

Cleco Corporation, through its subsidiaries, engages in the generation, transmission, distribution, and sale of electricity in Louisiana. As of December 31, 2009, it had ownership interest in 3 steam electric generating stations and 1 gas turbine with a combined name plate capacity of 1,359 megawatts, and a combined electric net generating capacity of 1,318 megawatts. The company served approximately 277,000 customers in 107 communities in the central and southeastern Louisiana. It also owns and operates a natural gas-fired merchant power plant, as well as has a 50% interest in another natural gas-fired merchant power plant located in Louisiana. Cleco Corporation was founded in 1934 and is based in Pineville, Louisiana.

Advisors' Opinion:

• [By Garrett Cook]

  Utilities sector was the top gainer in the US market on Thursday. Top gainers in the sector included Cleco (NYSE: CNL), Korea Electric Power (NYSE: KEP), and Regency Energy Partners LP (NYSE: RGP).

Hot Performing Stocks To Own For 2014: Reed Elsevier PLC(RUK)

Reed Elsevier PLC provides professional information solutions worldwide. The company?s Elsevier segment offers scientific, technical, and medical information solutions. This segment publishes science and technology research articles and book titles; and abstract and citation database of research literature, as well as offers information and workflow tools that help researchers generate insights in the advancement of scientific discovery. The Elsevier segment also provides medical journals, books, reference works, databases, and online information tools to medical researchers, doctors, nurses, allied health professionals, students, hospitals, research institutions, health insurers, managed healthcare organizations, and pharmaceutical companies. Its LexisNexis Risk Solutions segment offers data and analytics for the insurance industry; risk management, identity verification, fraud detection, credit risk management, and compliance solutions for financial institutions; invest igative solutions; and employment-related, resident and volunteer screening services. The company?s Lexisnexis Legal and Professional segment provides legal, tax, regulatory, and business information solutions. Its Reed Exhibitions segment organizes exhibitions and conferences for the broadcasting, TV, music, and entertainment; building and construction; electronics and electrical engineering; alternative energy, oil, and gas; engineering, manufacturing, and processing; gifts; interior design; IT and telecoms; jewelry; life sciences and pharmaceuticals; marketing; property and real estate; sports and recreation; and travel sectors. The company?s Reed Business Information segment provides data services, information, and marketing solutions to business professionals; produces industry critical data services, lead generation tools, and online community and job sites; and publishes business magazines. Reed Elsevier PLC was founded in 1894 and is based in London, the United Kin gdom.

Advisors' Opinion:

• [By Zarr Pacificador]

  A look at Reed Elsevier
  Today, I'm evaluating�Reed Elsevier� (LSE: REL  ) (NYSE: RUK  ) , a professional information solutions provider,�which currently trades at 743 pence. Here are my thoughts:

• [By Rupert Hargreaves]

  Today I am looking at�Reed Elsevier� (LSE: REL  ) (NYSE: RUK  ) to determine whether you should consider buying the shares at 734 pence.

• [By David O��ara]

  2. Reed Elsevier�
  Reed Elsevier� (LSE: REL  ) (NYSE: RUK  ) is a provider of "professional information solutions." Products include leading industry journals -- Reed Elsevier is publisher of both�The Lancet�and�Gray's Anatomy.